Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:05:56 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:XFOR - X4 PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XFOR - Q0.11.41·1.490.51.43-0.06-4.01,258.11,7021,8851.53  1.54  1.3826.958  1.4019:42:04Jun 1615 min RT 2¢

Recent Trades - Last 10 of 1885
Time ETExPriceChangeVolume
19:42:04Q1.45-0.0450
19:30:37Q1.45-0.045
19:26:16Q1.45-0.04123
19:25:01Q1.44-0.051
19:20:32Q1.45-0.044
19:17:22Q1.46-0.03178
19:16:24Q1.41-0.0813
19:12:01Q1.4697-0.02031
19:09:18Q1.40-0.091,188
19:09:18Q1.40-0.09120

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-16 08:00U:XFORNews ReleaseX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
2025-06-10 08:00U:XFORNews ReleaseX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
2025-06-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-14 16:12U:XFORNews ReleaseX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
2025-05-01 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
2025-04-24 08:03U:XFORNews ReleaseX4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
2025-04-24 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Reverse Stock Split
2025-04-23 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-25 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-03-11 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
2025-02-19 07:35U:XFORNews ReleaseX4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI(TM) (mavorixafor) in WHIM Syndrome in Select Middle East Countries
2025-02-06 07:35U:XFORNews ReleaseX4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
2025-02-03 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-24 07:36U:XFORNews ReleaseX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
2025-01-13 07:35U:XFORNews ReleaseX4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
2024-12-04 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
2024-12-03 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-26 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference
2024-11-14 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
2024-11-13 06:07U:XFORNews ReleaseX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update